Monday 1st December – Day 1 Main Conference - GMT (Greenwich Mean Time, GMTZ)
Starting from a brownfield and a greenfield, 2 brand new facilities for CAR-T production were built in Ghent in 2-3 years’ time. Building up the facility, recruiting and training people, building and qualifying processes and systems, passing HA inspections, meeting customer’s needs, an amazing experience for all involved.
- Frederik Buysse - VP-General Manager EU, Legend Biotech
- Snapshot into the investment landscape for CGT products and enabling technologies: Our expert investors reveal their bold predictions for CGT's trajectory through 2026
- Uncover game-changing investment opportunities in CGT as leading investors reveal which technologies are poised to disrupt healthcare and deliver exceptional returns
- Standing out in the crowd: Positioning for success in a competitive funding environment: What do investors need to see?
“Ask the Investor” interactive Q&A open discussion with our investor panel to get tips and tricks when pitching and their views on where innovation lies in the CGT field
- Volker Huppert - Chief Development Officer, Glycostem Therapeutics
- Anette Brass - Head of Process Development, Anocca AB
Spotlight Presentation – Calling all Technology Thought Leaders!
Whether you're increasing your company profile, launching a new product or focusing on new business development opportunities, collaborate with us to identify custom solutions to help you reach your goals.
Contact us today to learn more: RShah@informaconnectls.com
- Giovanni Ganendra - Upstream Process Science Senior Scientist, UCB
Spotlight Presentation – Calling all Technology Thought Leaders!
Whether you're increasing your company profile, launching a new product or focusing on new business development opportunities, collaborate with us to identify custom solutions to help you reach your goals.
Contact us today to learn more: RShah@informaconnectls.com
The CGT C-Level Forum provides a unique, powerful and valuable space for candidly sharing ideas and experiences between executives of ~20 CGT therapeutic development companies. The forum is designed to foster new ideas and create new relationships between attendees so that they can leave with tangible outcomes and that will drive their businesses and the sector forward.
An exclusive invite-only session, in a closed room setting, the forum will include 2-3 case studies discussing the right approach to engage and partner with pharma and industry. It will also include general discussion focussed on brainstorming solutions to the most pressing and current challenges of CEO/CSO/CBO/CMOs in the CGT sector.
- Subash Chander Govindasamy Ramamoorthy - Project Manager- Automation & Robotics, Cell & Gene Therapy, Bayer
- Natalie Gebken - Team lead, Fraunhofer Institute for Manufacturing Engineering and Automation
Spotlight Presentation – Calling all Technology Thought Leaders!
Whether you're increasing your company profile, launching a new product or focusing on new business development opportunities, collaborate with us to identify custom solutions to help you reach your goals.
Contact us today to learn more: RShah@informaconnectls.com
- Franck Gaston - Responsible Bioprocedes DSP, Genethon
- Yu-Tsan (Richard) Liu - Sr. Scientist, UCB Pharma
Spotlight Presentation – Calling all Technology Thought Leaders!
Whether you're increasing your company profile, launching a new product or focusing on new business development opportunities, collaborate with us to identify custom solutions to help you reach your goals.
Contact us today to learn more: RShah@informaconnectls.com
Through a series of 15 minute case studies this session will focus on the latest advances in next-generation therapies.
Explore cutting-edge preclinical and clinical case studies driving the future of cell and gene therapy.
Discover how data-driven innovation is transforming therapy development, from control and targeting to tackling undruggable diseases.
Unpack the challenges vs. traditional approaches, advancements in new modalities, and the manufacturing needs shaping commercialisation of future therapies.
Key Case Studies Areas Include:
- Gamma Delta T Cells & T Cell Engagers
- mRNA, RNA, & NK Therapies
- Multiplex & Combination Cell Therapies
- Solid Tumours & Expanding Disease Areas (Autoimmune, Neurology, Cardiometabolic)
- Regine Heilbronn - Co-Founder and CEO, EpiBlok Therapeutics
- Dethardt Müeller - Chief Technology Officer - CMC, Abalos Therapeutics GmbH
- Lindsay Davies - Chief Scientific Officer, NextCell Pharma
- Marina Tarunina - Research Director, Plasticell Ltd
- Eric Halioua - President & Chief Executive Officer, PDC*line Pharma
- Building with the End in Mind: Key takeaways from embedding market and patient needs from day one
- Fast-Tracking Development: What a seamless integration of R&D and process development speeds up timelines
- Cost Reduction Innovations: Key drivers in reducing CGT production costs
- Choosing the Best Manufacturing Model: External, internal, or shared capacity—what’s the winning strategy?
- Driving Down CoGs: Game-changing improvements in process, automation, and scaling without compromising on quality.
- Scaling Smart: Navigating the balance between speed, cost, and quality in manufacturing.
- Harnessing Modular & Advanced Tech: How next-gen technologies are supercharging production.
- Analytics & Automation in Action: Tackling batch variability and scaling hurdles head-on.
- Securing the Supply Chain: Mitigating risks in raw materials and critical components.
- Batch Consistency at Scale: Unlocking the secret to flawless, consistent production.
- Scaling for Rare & Common Diseases: Addressing challenges and opportunities
- Cost-Effectiveness for Larger Populations: Balancing cost-cutting strategies with uncompromising quality.
- Best Practices: Reducing CoGs and improving manufacturing efficiency in gene therapies
- Mirjana Cvijanovic - Scientific Sr. Manager, Johnson & Johnson